Jim O'Neill
At a time when antimicrobial resistance threatens public health and our long-term economic well-being, tax policies favor financial engineering at the expense of developing new antibiotics. Similarly perverse incentives are at the heart of out-of-control public spending.
LONDON—Two recent conversations confirmed my suspicion that too many experts are operating in silos and often failing to connect the dots.